Qu JJ - Search Results

1

Ivacaftor, a CFTR potentiator, synergizes with osimertinib against acquired resistance to osimertinib in NSCLC by regulating CFTR-PTEN-AKT axis.

Li YK, Ge FJ, Liu XN, Zeng CM, Qian MJ, Li YH, Zheng MM, Qu JJ, Fang LJ, Lu JJ, Yang B, He QJ, Zhou JY, Zhu H. Li YK, et al. Among authors: qu jj. Acta Pharmacol Sin. 2024 Dec 3. doi: 10.1038/s41401-024-01427-0. Online ahead of print. Acta Pharmacol Sin. 2024. PMID: 39627385

2

CD57-positive CD8 + T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer.

Sun W, Qiu F, Zheng J, Fang L, Qu J, Zhang S, Jiang N, Zhou J, Zeng X, Zhou J. Sun W, et al. NPJ Precis Oncol. 2024 Jan 31;8(1):25. doi: 10.1038/s41698-024-00513-0. NPJ Precis Oncol. 2024. PMID: 38297019 Free PMC article.

3

CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy.

Qu J, Wu B, Chen L, Wen Z, Fang L, Zheng J, Shen Q, Heng J, Zhou J, Zhou J. Qu J, et al. J Exp Clin Cancer Res. 2024 May 3;43(1):134. doi: 10.1186/s13046-024-03046-3. J Exp Clin Cancer Res. 2024. PMID: 38698468 Free PMC article.

4

CD161⁺CD127⁺CD8⁺ T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus.

Qu J, Li Y, Wu B, Shen Q, Chen L, Sun W, Wang B, Ying L, Wu L, Zhou H, Zhou J, Zhou J. Qu J, et al. Oncoimmunology. 2024 Jun 27;13(1):2371575. doi: 10.1080/2162402X.2024.2371575. eCollection 2024. Oncoimmunology. 2024. PMID: 38952673 Free PMC article.

5

Efficacy and Safety of Anlotinib in EGFR-Positive Patients with Advanced Lung Adenocarcinoma Compared with Chemotherapy: A Retrospective Study.

Cai C, Shen Q, Shao J, Qu J, Zhou S, Zhou J. Cai C, et al. Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241279111. doi: 10.1177/15330338241279111. Technol Cancer Res Treat. 2024. PMID: 39175430 Free PMC article.

6

Prognostic Nomogram for Predicting Survival in Asian Patients With Small-Cell Lung Cancer: A Comprehensive Population-Based Study and External Verification.

Xia Y, Qu J, Wang Y, Zhu Y, Zhou J, Zhou J. Xia Y, et al. Clin Respir J. 2024 Nov;18(11):e70021. doi: 10.1111/crj.70021. Clin Respir J. 2024. PMID: 39520246 Free PMC article.

7

Identifying risk factors and biomarkers for severe CIP in lung cancer patients- a retrospective case series study.

Wu G, Qu J, Zheng J, Wu B, Wang T, Gan Y, Jiang N, Li Y, Liu J, Zhou J, Zhou J. Wu G, et al. Immunotherapy. 2024;16(18-19):1131-1140. doi: 10.1080/1750743X.2024.2429369. Epub 2024 Nov 26. Immunotherapy. 2024. PMID: 39589860

8

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation.

Qu J, Shen Q, Li Y, Kalyani FS, Liu L, Zhou J, Zhou J. Qu J, et al. Front Oncol. 2022 Jun 22;12:911303. doi: 10.3389/fonc.2022.911303. eCollection 2022. Front Oncol. 2022. PMID: 35814395 Free PMC article.

9

Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.

Qu J, Kalyani FS, Shen Q, Yang G, Cheng T, Liu L, Zhou J, Zhou J. Qu J, et al. J Oncol. 2022 Sep 26;2022:3645489. doi: 10.1155/2022/3645489. eCollection 2022. J Oncol. 2022. PMID: 36199793 Free PMC article.

10

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report.

Shen Q, Qu J, Chen Z, Zhou J. Shen Q, et al. Front Oncol. 2021 Dec 2;11:760097. doi: 10.3389/fonc.2021.760097. eCollection 2021. Front Oncol. 2021. PMID: 34926262 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65 results

Search Page

Filters